ClosedResearch announcementOpportunity HT942526ALSRPTIA

DoW Amyotrophic Lateral Sclerosis Research Program, Therapeutic Idea Award

Defense Health Agency Contracting Activity - DHACA · Department of Defense

At a glance

DoW Amyotrophic Lateral Sclerosis Research Program, Therapeutic Idea Award is a closed federal grant opportunity from the Defense Health Agency Contracting Activity - DHACA (Department of Defense). The application deadline was September 30, 2026. Total estimated funding is $10.1M across about 12 awards. The notice is unrestricted by applicant type, subject to any clarifications in the notice. Cost sharing is not required. It is funded under Assistance Listing 12.420 (Military Medical Research and Development).

Summary assembled from the official notice's fields. The official notice governs.

Key facts

May 4, 2026Posted
Sep 30, 2026Application deadline
Oct 30, 2026Archivednext date

Posted: May 4, 2026
Close date: Sep 30, 2026
Archive date: Oct 30, 2026
Award floor: Not specified
Award ceiling: Not specified
Est. total funding: $10,080,000
Implied average award: $840,000 calculated
Expected awards: 12
Cost sharing: Not required
Funding instrument: Grant
Opportunity category: Discretionary

Typical awards for this program (SAM.gov listing for ALN 12.420, not this notice): This Assistance Listing supports approximately 30 or more programs each year. Overall, awards are expected to range from $100,000 to $20M (consortium) depending on the funding priorities, anticipated number of awards, and project activity/scope within each program for an award period, on average, of 3 to 4 years. The maximum award amount, if any, is specified in each Program Announcement or Broad Agency Announcement.

Implied average = estimated total funding ÷ expected number of awards, calculated by GrantsJunction. Actual awards vary.

Who can apply

Unrestricted (any entity type)

Can your organization apply?

A quick check against the listed applicant types — other requirements in the notice still apply.

Based on the published notice. Review the official notice for complete eligibility requirements.

What it funds

Official synopsis as published by the agency, formatted for readability.

Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Therapeutic Idea Award (TIA) supports new, innovative, high-risk, high-gain ideas aimed at amyotrophic lateral sclerosis (ALS) drug or therapy discovery. The studies supported by this award mechanism are expected to be hypothesis-driven and generate preliminary data for future avenues of therapeutic investigation.

Distinctive Features: Potential impact and innovation are important features of the TIA. Applications may demonstrate the ability to achieve interpretable results in the absence of preliminary data supporting the hypothesis. While the inclusion of preliminary data is not prohibited, the strength of the application should rely on the approach.

Full announcement & documents

The full announcement has the complete rules — page limits, required attachments, evaluation criteria and any letter-of-intent dates. Files download directly from Grants.gov.

FY26 ALSRP TIA Program AnnouncementFull Announcement · HT942526ALSRPTIA_GG.pdfPDF · 687 KB

Assistance Listing

What is an ALN?

12.420Military Medical Research and DevelopmentProgram →

Reported obligations under ALN 12.420

Historical data · not a prediction

FY24

$1.48B

FY25

$1.2B

FY26

— est.

Source: SAM.gov Assistance Listing 12.420. Program-wide totals, not awards from this specific opportunity.

Who was funded under ALN 12.420

Historical data · not a prediction

Since October 1, 2023, 6,147 grant awards had funding actions under Military Medical Research and Development, with 2,218 sub-awards passed on to other organizations. These are program-wide awards, not awards from this specific notice.

THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.$139M
THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER$118M
REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE$81.8M
THE JOHNS HOPKINS UNIVERSITY$72.4M
UNIVERSITY OF CALIFORNIA, LOS ANGELES$62.2M

Recipients, states, recent awards and sub-awards →Source: USAspending.gov.

Agency contact (as published)

Jamie Shortall Grant Officer
help@eBRAP.org
301-619-2393

Quick answers

Who is eligible to apply for “DoW Amyotrophic Lateral Sclerosis Research Program, Therapeutic Idea Award”?

The notice lists eligibility as unrestricted — open to any type of entity — subject to clarifications in the notice's additional eligibility information.

How much funding is available through “DoW Amyotrophic Lateral Sclerosis Research Program, Therapeutic Idea Award”?

Per the notice, total estimated program funding is $10,080,000 and the agency expects to make about 12 awards.

How do I apply for “DoW Amyotrophic Lateral Sclerosis Research Program, Therapeutic Idea Award”?

Applications are submitted through the official source, not through GrantsJunction. Open the official notice on Grants.gov (opportunity HT942526ALSRPTIA), and review the full announcement and application package. Organizations applying through Grants.gov generally need an active SAM.gov registration and a Grants.gov account, which can take several weeks to set up.

Matched on shared Assistance Listings, agency, categories and eligible applicant types.

Closes in 5 daysResearchALN 12.420